BRISTOL MYERS SQUIBB CO (BMY)
BRISTOL MYERS SQUIBB CO (BMY) from its SEC filings: 2025 revenue $48.2 billion (-0% vs the year before), net margin 15%, free cash flow $12.8 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $48.2 billion |
| Revenue growth | -0% |
| Net income | $7.1 billion |
| Net margin | 14.6% |
| Free cash flow | $12.8 billion |
| Diluted EPS | $3.46 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $8.7 billion |
| Long-term debt | $42.1 billion |
| Share count, 1 year | +0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.